Researchers discover treatable cause of severe anemia associated with a cancer therapy

Researchers at the Mount Sinai Tisch Cancer Center have identified a previously underrecognized folate deficiency that may cause severe anemia in some patients receiving PARP inhibitors, a widely used class of targeted cancer therapies.

Their findings, published in the latest issue of the journal Blood Red Cells & Iron, suggest that routine screening and treatment with folic acid could help many patients avoid blood transfusions, hospitalizations and interruptions to their cancer treatment. ...